Study Identifies Predictors of Rapid Renal Decline in ADPKD
Creatinine alone does not reliably predict renal decline in the AKPKD population, according to investigators.
ADPKD
ADPKD Progression to End-Stage Kidney Disease Varies by Race/Ethnicity
Autosomal dominant polycystic kidney disease progresses to kidney failure faster in Hispanic patients than in those of other races or ethnicities, a study found.
Patient Interviews Highlight Challenges in ADPKD Management
Nephrologists rarely explained the clinical meaning of rapid progression, according to patients.
ADPKD Death Rates Differ by Race, Ethnicity
Study findings fill an important knowledge gap in ADPKD mortality in the United States, according to researchers.
Urine-to-Plasma Urea Ratio Predicts ADPKD Progression
The early morning fasting urine-to-plasma urea ratio reflects the kidneys’ urine-concentrating capacity, which may decline early in ADPKD, according to investigators.
Lower Bicarbonate in ADPKD Linked to Worsening Kidney Outcomes
A study of patients with ADPKD found that each 1 mmol/L decrease in serum bicarbonate was significantly associated with a 21% increased risk for worsening kidney function.
Orphan Drug Status Granted to Potential Polycystic Kidney Disease Treatment
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations of the PKD1 and PKD2 genes.
Tolvaptan Lowers Kidney Stone Risk in ADPKD
Tolvaptan improves the urinary lithogenic risk profile of patients with autosomal dominant polycystic kidney disease, according to researchers.
Bardoxolone Gets Orphan Drug Status for Autosomal Dominant Polycystic Kidney Disease
The FDA has granted bardoxolone methyl (bardoxolone; Reata Pharmaceuticals) Orphan Drug designation for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
- Loading...
Loading...
Next post in Chronic Kidney Disease (CKD)
Loading... 
Loading...